
Email from MHRA to NNNG request for expert advice

From [REDACTED]
Date Mon 14/10/2024 15:09
To NNNG <info@nnng.org.uk>
Cc [REDACTED]

Dear [REDACTED]

Thank you for your email.

I can confirm that the MHRA did not receive a response and haven't had any interaction with any NNNG committee members on this matter.

Whilst we appreciate that the original correspondence was sent some time ago now, the MHRA keeps the safety of all medical devices under continual review, and would welcome a response to the previously shared questions if the NNNG is able to provide one.

Kind regards,

<http://www.gov.uk/mhra>
[Follow us on social media](#)

From: Info <info@nnng.org.uk>

Sent: 04 October 2024 22:40

To: [REDACTED]

Cc: [REDACTED]

Subject: Re: Email from MHRA to NNNG request for expert advice

You don't often get email from info@nnng.org.uk. [Learn why this is important](#)

Dear [REDACTED]

I found this email in our inbox, my apologies if it was not responded to. There have been some changes to committee members since your email, I'd like to check if you had a response or interaction with any NNNG committee members on this matter?

Kind regards,

Sent on behalf of the NNNG Committee

[REDACTED]

From: [REDACTED]
Sent: 09 December 2022 17:10
To: info@nnng.org.uk <info@nnng.org.uk>
Cc: [REDACTED]
Subject: Email from MHRA to NNNG request for expert advice

Dear NNNG Team,
I hope you are well.

My name is [REDACTED] and I am a benefit risk assessor within the safety and surveillance team in the MHRA (Medicines and Healthcare products Regulatory Agency), the MHRA regulates medicines, medical devices and blood components for transfusion in the UK and is recognised globally as an authority in its field, the agency also plays a leading role in protecting and improving public health and supports innovation through scientific research and development.

I am writing to you as enteral feeding experts for your opinion on the following regarding the **CORTRAK 2 Enteral Access System**.

1. We would be interested to hear your opinion on the role of NG tube placement aids such as the Cortrak 2 Enteral Access System in the safe placement and tip confirmation of NG tubes.
2. Earlier this year the manufacturer of the Cortrak 2 issued a FSN (attached) in which they alert users they are updating their labelling and training materials to emphasise that **'confirmation of NG/NI tubes placed using CORTRAK* 2 should be confirmed per institutional protocol.'** Could you please provide any comments on this notice: i.e. is there sufficient information included for users to be able to adapt or create institutional protocols? If there is some missing information or you have some concerns, could you provide any details?
3. Do you have any plans to update your organisation's current (2016) good practice guidelines on Safe Insertion and Ongoing Care of Nasogastric (NG) Feeding Tubes in Adults?

Would it also be possible to set up a call for further discussion?

Please let me know if you require any further information and could I ask for you to please aim to provide a response by **Friday 23rd of December 2022**.

Kind Regards,

[REDACTED]

[REDACTED]

[Read our guidance on coronavirus \(COVID-19\)](#).



DISCLAIMER This email and any files transmitted with it are confidential. If you are not the intended recipient, any reading, printing, storage, disclosure, copying or any other action taken in respect of this email is prohibited and may be unlawful. If you are not the intended

recipient, please notify the sender immediately by using the reply function and then permanently delete what you have received. Incoming and outgoing email messages are routinely monitored for compliance with the Department of Health's policy on the use of electronic communications. For more information on the Department of Health's email policy, click [**DHTermsAndConditions**](#)

DISCLAIMER This email and any files transmitted with it are confidential. If you are not the intended recipient, any reading, printing, storage, disclosure, copying or any other action taken in respect of this email is prohibited and may be unlawful. If you are not the intended recipient, please notify the sender immediately by using the reply function and then permanently delete what you have received. Incoming and outgoing email messages are routinely monitored for compliance with the Department of Health's policy on the use of electronic communications. For more information on the Department of Health's email policy, click [**DHTermsAndConditions**](#)

DISCLAIMER This email and any files transmitted with it are confidential. If you are not the intended recipient, any reading, printing, storage, disclosure, copying or any other action taken in respect of this email is prohibited and may be unlawful. If you are not the intended recipient, please notify the sender immediately by using the reply function and then permanently delete what you have received. Incoming and outgoing email messages are routinely monitored for compliance with the Department of Health's policy on the use of electronic communications. For more information on the Department of Health's email policy, click [**DHTermsAndConditions**](#)